EMN Secures $5 Million Series A to Revolutionize Surgical Nutrition
Enhanced Medical Nutrition, Inc. (EMN), a pioneering food-as-medicine company, has successfully secured a USD $5 million over-subscribed Series A financing round. This significant investment was led by dsm-firmenich Venturing and the Corporate Venture Capital (CVC) arm of Ajinomoto Co., Inc., with additional participation from PeakBridge, Elder Ventures, angel investors, and existing shareholders.
The funds raised will be utilized to scale the expansion of ENROUTE, an innovative nutrition program specifically designed for the dietary management of surgery. EMN is committed to revolutionizing the standard of care in surgery by leveraging nutrition technology to reduce risk, accelerate recovery, and enhance overall patient outcomes.
EMN’s mission is to improve surgical outcomes through evidence-based medical nutrition products. The company’s flagship product, ENROUTE, is a proprietary, evidence-based nutrition program tailored to address the unique nutritional requirements of patients undergoing surgery. ENROUTE works by providing targeted nutrients and addressing deficiencies to support the body’s healing processes, including muscle mass, tissue repair, and immune function. It is administered pre- and post-operatively and seamlessly integrates into surgical protocols, enabling healthcare providers to incorporate medical nutrition for their patients.
The investment in EMN marks a strategic partnership with dsm-firmenich Venturing and Ajinomoto’s CVC arm, reflecting their shared vision of leveraging functional ingredients and empowering market-ready solutions to improve human health. Ajinomoto, an amino acid technology company, has a strong interest in the impact of nutritional supplementation for surgical patients, from prehabilitation to rehabilitation to healthy aging. This investment aligns with Ajinomoto’s ongoing commitment to medical nutrition.
PeakBridge’s participation in the funding round underscores their commitment to supporting innovative solutions in the food-as-medicine space. EMN’s approach brings an essential and timely innovation to an underserved market, one that will significantly improve patient outcomes and drive meaningful progress in healthcare nutrition.
EMN, based in Toronto, Ontario, and Chicago, Illinois, is dedicated to pioneering a new standard of care where nutrition technology is leveraged to reduce risk, accelerate recovery, and enhance overall patient outcomes. The company’s focus on scientific validation and patient-centric innovation aligns with the vision of its investors, positioning EMN to significantly impact the standard of care in surgery.
The successful Series A funding round marks an exciting step for EMN as it expands its reach and delivers value to a growing market. With this investment, EMN is poised to transform surgical care and improve patient outcomes by integrating nutrition as a critical component of healthcare.
See more funded startups in USA.